Posted by Michael Wonder on 27 Jul 2023
Defender Pharmaceuticals announces submission of new drug application to FDA with intranasal scopolamine for prevention of nausea and vomiting induced by motion in adults
26 July 2023 - Submission based on five Phase III clinical trials, including overwhelmingly positive results from the -33 Phase 3 study.
Defender Pharmaceuticals today announced that the Company has submitted its first new drug application to the US FDA with intranasally administered scopolamine gel (DPI-386 nasal gel) for prevention of nausea and vomiting induced by motion in adults.
